Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay

Journal of Clinical Virology, Journal Year: 2021, Volume and Issue: 139, P. 104820 - 104820

Published: April 14, 2021

Neutralization tests (NT) are the gold standard for detecting and quantifying anti-SARS-CoV-2 neutralizing antibodies (NAb), but their complexity restricts them to research settings or reference laboratories. Antibodies against S protein receptor binding domain (RBD) have been shown confer a activity SARS-CoV-2. Assays quantitatively measuring anti-S1-RBD-SARS-CoV-2 could be of great value NAb screening potential donors convalescent-phase plasma therapy, assessing natural vaccine-induced immunity, stratifying individuals vaccine receipt, documenting response. Elecsys Anti-SARS-CoV-2 (Elecsys-S), high-throughput automated electrochemiluminescence double-antigen sandwich immunoassay quantitative measurement pan-anti-S1-RBD-SARS-CoV-2 antibodies, was evaluated NT on 357 patients with PCR-confirmed SARS-CoV-2 infection. performed in BSL-3 laboratory using Slovenian isolate; titer ≥1:20 considered positive. Elecsys-S detected 352/357 (98.6 %) samples. were identified by 257/357 (72 The Elecsys-S/NT agreement moderate (Cohen's kappa 0.56). High (≥1:160) 106/357 (30 Elecsys-S's antibody concentrations correlated individual categories (the lowest NT-negative samples highest 1:1,280), cutoff reasonable prediction generated after infection established (133 BAU/mL). Although should remain candidates donors, selected commercial assays optimized cutoff, like Elecsys-S, used rapid, automated, large-scale clinically relevant levels as suitable donors.

Language: Английский

---

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing

Clinical Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: March 13, 2024

The role of serologic testing for SARS-CoV-2 has evolved during the pandemic as seroprevalence in global populations increased. Infectious Diseases Society America (IDSA) convened an expert panel to perform a systematic review coronavirus disease 2019 (COVID-19) serology literature and construct updated best practice guidance related testing. This guideline is update fourth series rapid, frequently COVID-19 guidelines developed by IDSA.

Language: Английский

---

COVID-19 Antibody Tests: A Valuable Public Health Tool with Limited Relevance to Individuals

Trends in Microbiology, Journal Year: 2020, Volume and Issue: 29(3), P. 214 - 223

Published: Nov. 7, 2020

Antibody tests for detecting past infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have many uses public health decision making, but demand has largely come from individual consumers. This review focuses on the relevance of antibody tests: their accuracy in prior infection, what SARS-CoV-2 can currently infer about future immunity or possible medical sequelae, and potential importance vaccine selection screening. Given uncertainty (quality, level, positive predictive value) those might indicate immunologically (durability antibodies necessity protection reinfection), seropositive test results should not be used to inform testing remain a tool at this time.

Language: Английский

---

Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect

Journal of Clinical Virology, Journal Year: 2020, Volume and Issue: 133, P. 104663 - 104663

Published: Oct. 27, 2020

Language: Английский

---

COVID-19—Lessons Learned and Questions Remaining

Clinical Infectious Diseases, Journal Year: 2020, Volume and Issue: 72(12), P. 2225 - 2240

Published: Oct. 23, 2020

Abstract In this article, the editors of Clinical Infectious Diseases review some most important lessons they have learned about epidemiology, clinical features, diagnosis, treatment and prevention SARS-CoV-2 infection identify essential questions COVID-19 that remain to be answered.

Language: Английский

---

Severe Acute Respiratory Syndrome Coronavirus‐2

Published: Nov. 22, 2024

Language: Английский

---

Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain

Journal of Clinical Virology, Journal Year: 2021, Volume and Issue: 137, P. 104784 - 104784

Published: March 7, 2021

Accurate anti-SARS-CoV-2 assays are needed to inform diagnostic, therapeutic, and public health decisions. The first manufacturer-independent head-to-head comparison of two rapid high-throughput automated electrochemiluminescence double-antigen sandwich immunoassays targeting total antibodies against different viral proteins, Elecsys Anti-SARS-CoV-2 (Elecsys-N) S (Elecsys-S) (Roche Diagnostics), was performed in a routine setting during the exponential growth phase epidemic's second wave.The diagnostic specificity Elecsys-N Elecsys-S initially evaluated on panel 572 pre-COVID-19 samples, showing 100 % both assays. Elecsys-N/Elecsys-S used 3,416 consecutive blood samples from individuals that were tested for presence within commercial out-of-pocket serologic testing.Elecsys-N/Elecsys-S showed overall agreement 98.68 (3,371/3,416; 95 CI, 98.23-99.03 %), positive 95.16 (884/929; 93.52-96.41 high kappa value 0.996 (95 0.956-0.976). Previous SARS-CoV-2 PCR positivity identified 14/24 (58.3 %) negative/Elecsys-S 4/21 (19.0 positive/Elecsys-S negative individuals.The excellent highly specific An important question is whether laboratories offering antibody could benefit combining assays; if so, should use be concomitant or sequential-and, latter case, which order? Based our results, we favor over sequential when testing high-incidence settings; example, stationary COVID-19 epidemic.

Language: Английский

---

Impact of COVID-19 on Pediatric Immunocompromised Patients

Pediatric Clinics of North America, Journal Year: 2021, Volume and Issue: 68(5), P. 1029 - 1054

Published: May 26, 2021

---

Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia

International Journal of Infectious Diseases, Journal Year: 2020, Volume and Issue: 101, P. 191 - 193

Published: Sept. 28, 2020

ObjectivesWe investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 2019, an endemic area the Caribbean Colombian region.MethodsA total 127 sera obtained six individuals were included this study: Group A: with confirmed infection; B: symptoms suggestive COVID-19 or asymptomatic contacts patients; C: acute recent dengue virus D: Zika E: previous F: exposure spotted fever group rickettsiae.ResultsOverall, A, B, D showed 92%, 75%, 26% samples, respectively; furthermore, C, E, F 100% seronegativity.ConclusionsWe found serological cross-reactivity test. Further studies are needed evaluate whether cross-reaction is maintained time nonacute its effect serosurveys areas for arbovirus.

Language: Английский

---

Detection of SARS-CoV-2 IgG antibodies in dried blood spots

Diagnostic Microbiology and Infectious Disease, Journal Year: 2021, Volume and Issue: 101(1), P. 115425 - 115425

Published: May 13, 2021

Language: Английский

---